KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Historic Long-Term Deferred Tax for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q2 2019 value amounting to $391.9 million.

  • Amneal Pharmaceuticals' Long-Term Deferred Tax rose 486.37% to $391.9 million in Q2 2019 from the same period last year, while for Jun 2019 it was $391.9 million, marking a year-over-year increase of 486.37%. This contributed to the annual value of $373.2 million for FY2018, which is 4145445.43% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Long-Term Deferred Tax of $391.9 million as of Q2 2019, which was up 486.37% from $382.9 million recorded in Q1 2019.
  • In the past 5 years, Amneal Pharmaceuticals' Long-Term Deferred Tax registered a high of $391.9 million during Q2 2019, and its lowest value of $898000.0 during Q4 2017.
  • Its 3-year average for Long-Term Deferred Tax is $314.8 million, with a median of $373.4 million in 2018.
  • In the last 5 years, Amneal Pharmaceuticals' Long-Term Deferred Tax skyrocketed by 4145445.43% in 2018 and then surged by 486.37% in 2019.
  • Over the past 3 years, Amneal Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $898000.0 in 2017, then soared by 41454.45% to $373.2 million in 2018, then grew by 5.02% to $391.9 million in 2019.
  • Its last three reported values are $391.9 million in Q2 2019, $382.9 million for Q1 2019, and $373.2 million during Q4 2018.